Floor-Schreudering Annemieke, Geerts Arjen F J, Aronson Jeffrey K, Bouvy Marcel L, Ferner Robin E, De Smet Peter A G M
SIR Institute for Pharmacy Practice and Policy, Theda Mansholtstraat 5B, 2331 JE, Leiden, The Netherlands,
Eur J Clin Pharmacol. 2014 Mar;70(3):313-8. doi: 10.1007/s00228-013-1612-7. Epub 2013 Dec 5.
Inconsistencies and omissions in drug-drug interaction (DDI) management guidelines may lead to harm and suboptimal therapy. The purpose of this study was to define a checklist for DDI management guidelines to help developers produce high-quality guidelines that will support healthcare providers in clinical practice.
We carried out a two-round Delphi process with an international panel of healthcare providers, most of whom are pharmacists involved in providing DDI information, in order to select those items that should be addressed in DDI management guidelines (including grading systems that could be used).
Twenty-three panellists reached consensus on 19 items in two main domains. These were consolidated into a checklist of 15 elements for standardized reporting in management guidelines. For each element a description is provided to specify what information should be documented in that specific element.
It was possible to reach a broad consensus on which relevant items should be included in a checklist for the development of DDI management guidelines.
药物相互作用(DDI)管理指南中的不一致和遗漏可能导致伤害和治疗效果不佳。本研究的目的是为DDI管理指南制定一份清单,以帮助开发者制定高质量的指南,为临床实践中的医疗服务提供者提供支持。
我们与一个国际医疗服务提供者小组进行了两轮德尔菲法,其中大多数是参与提供DDI信息的药剂师,以选择那些应在DDI管理指南中涉及的项目(包括可使用的分级系统)。
23名小组成员就两个主要领域的19个项目达成了共识。这些被整合为一份包含15个要素的清单,用于管理指南中的标准化报告。为每个要素提供了描述,以明确在该特定要素中应记录哪些信息。
就DDI管理指南制定清单应包括哪些相关项目达成广泛共识是可能的。